Gemini Therapeutics (GMTX) Competitors $40.27 +1.54 (+3.98%) As of 04/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. ROIV, LNTH, TGTX, RVMD, BBIO, LEGN, BPMC, SRPT, TLX, and AXSMShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Legend Biotech Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Gemini Therapeutics (NASDAQ:GMTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking. Is GMTX or ROIV more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Roivant Sciences -119.54%-14.05%-12.81% Which has more volatility and risk, GMTX or ROIV? Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Do institutionals and insiders hold more shares of GMTX or ROIV? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor GMTX or ROIV? In the previous week, Roivant Sciences had 9 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 0 mentions for Gemini Therapeutics. Roivant Sciences' average media sentiment score of 1.26 beat Gemini Therapeutics' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Roivant Sciences Positive Which has better valuation and earnings, GMTX or ROIV? Roivant Sciences has higher revenue and earnings than Gemini Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Gemini Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-40.27Roivant Sciences$122.59M58.56$4.35B-$0.15-67.07 Do analysts prefer GMTX or ROIV? Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 73.96%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer GMTX or ROIV? Roivant Sciences received 35 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 78.26% of users gave Roivant Sciences an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformGemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Roivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% SummaryRoivant Sciences beats Gemini Therapeutics on 14 of the 18 factors compared between the two stocks. Remove Ads Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-40.276.7921.7317.81Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book13.935.866.464.00Net Income-$71.87M$141.86M$3.20B$247.23M7 Day Performance17.47%4.50%2.85%1.45%1 Month Performance-21.07%-12.65%-8.55%-6.24%1 Year Performance31.95%-11.06%10.46%0.60% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$40.27+4.0%N/A+26.5%$1.74BN/A-40.2730Gap UpHigh Trading VolumeROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3411 of 5 stars$95.45+5.0%$129.43+35.6%+70.6%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3148 of 5 stars$37.25-0.3%$40.67+9.2%+177.4%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.8147 of 5 stars$31.40+0.3%$65.23+107.7%+2.2%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.5716 of 5 stars$30.67-2.2%$52.64+71.6%+32.9%$5.83B$221.90M-10.76400Analyst ForecastGap DownLEGNLegend Biotech2.409 of 5 stars$30.25-5.5%$79.00+161.2%-34.8%$5.56B$627.24M-31.841,070Positive NewsGap UpBPMCBlueprint Medicines2.6341 of 5 stars$80.20-1.8%$124.95+55.8%-4.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6725 of 5 stars$52.40-3.7%$163.18+211.4%-54.0%$5.08B$1.90B41.92840Short Interest ↑Gap DownHigh Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5823 of 5 stars$98.50-0.4%$169.80+72.4%+52.2%$4.80B$385.69M-16.44380Analyst Revision Remove Ads Related Companies and Tools Related Companies Roivant Sciences Alternatives Lantheus Alternatives TG Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Sarepta Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GMTX Stock Free GMTX Stock Alerts